BioReg­num: The fog of M&A. What con­sti­tutes a le­git buy­out ‘scoop’ these days?


The view from End­points

The com­pe­ti­tion be­tween Reuters, Bloomberg and the Wall Street Jour­nal to break the next big M&A sto­ry keeps low­er­ing the bar on what qual­i­fies as a sig­nif­i­cant new move in the bid­ding process.

Reuters is off and run­ning with one of the lat­est scoops, re­port­ing that Mer­ck has joined a group of at least five com­pa­nies that have “sub­mit­ted in­di­ca­tions of in­ter­est” for Medi­va­tion. There’s no clear idea just what that means, or where Mer­ck $MRK might fit in the auc­tion af­ter Sanofi went pub­lic with its last of­fer. But we’re all talk­ing about it.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.